companydirectorylist.com  Global Business Directories and Company Directories
Search Business,Company,Industry :


Country Lists
USA Company Directories
Canada Business Lists
Australia Business Directories
France Company Lists
Italy Company Lists
Spain Company Directories
Switzerland Business Lists
Austria Company Directories
Belgium Business Directories
Hong Kong Company Lists
China Business Lists
Taiwan Company Lists
United Arab Emirates Company Directories


Industry Catalogs
USA Industry Directories












Company Directories & Business Directories

BOSSTEC COMMUNICATIONS SYSTEMS

BRAMPTON-Canada

Company Name:
Corporate Name:
BOSSTEC COMMUNICATIONS SYSTEMS
Company Title:  
Company Description:  
Keywords to Search:  
Company Address: 19 Grovewood Dr,BRAMPTON,ON,Canada 
ZIP Code:
Postal Code:
L7A1R6 
Telephone Number: 9058407988 
Fax Number:  
Website:
 
Email:
 
USA SIC Code(Standard Industrial Classification Code):
173108 
USA SIC Description:
Telephone-Installations 
Number of Employees:
5 to 9 
Sales Amount:
$500,000 to $1 million 
Credit History:
Credit Report:
Unknown 
Contact Person:
 
Remove my name



copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)









Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Your Subject:
Your Comment or Review:
Security Code:



Previous company profile:
BOTTING A J & ASSOCIATES INC
BOTBOL, CHARLES DDS
BOSTON PIZZA
Next company profile:
BOSSTEC COMMUNICATIONS SYSTEMS CORP
BOSSIN, R M DDS
BOSSCO PLUMBING & HEATING LTD










Company News:
  • Acute Lymphoblastic Leukemia (ALL) Treatment Protocols
    Treatment protocols for acute lymphoblastic leukemia (ALL) are provided below, including general treatment recommendations and commonly used treatment recommendations, as well as information
  • Typical Treatment of Acute Lymphocytic Leukemia (ALL)
    The main treatment for acute lymphocytic leukemia (ALL) in adults is often chemotherapy, although other treatments might be helpful in some situations Learn more about what to expect here
  • Acute Lymphoblastic Leukemia, Version 2. 2024, NCCN Clinical Practice . . .
    This selection from the NCCN Guidelines for ALL focuses on the treatment of newly diagnosed Philadelphia chromosome (Ph)-negative B-cell ALL (B-ALL) in adults (to view the complete and most recent version of these Guidelines, including recommendations for AYA patients, visit NCCN org)
  • Acute Lymphoblastic Leukemia Treatment - NCI - National Cancer Institute
    Acute lymphoblastic leukemia (ALL) treatment options include chemotherapy, radiation therapy, stem cell transplant, and or targeted therapy Get detailed information about newly diagnosed and recurrent ALL in this expert-reviewed summary
  • Leukemia-ALL. indd - Cancer Therapy Advisor
    Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly The cancer treatment regimens below may include both U S Food and Drug Administration-approved and unapproved indications regimens
  • Treatment of Adult Acute Lymphoblastic Leukemia
    Standard induction of adult ALL includes at least a gluco-corticoid, vincristine, an anthracycline and probably asparaginase In response to pediatric results that show a decreased central nervous system (CNS) relapse rate and improved survival, 15 prednisone is now being replaced by dexamethasone
  • Report or manual template - Alberta Health Services
    Classification and Prognostication Patients should be classified as having B-cell or T-cell ALL based upon immunophenotyping results Pre-treatment risk stratification should be ascertained for all patients using age and cytogenetics FISH and or molecular studies
  • Management of Adult Acute Lymphoblastic Leukemia: A Review
    The novel therapies include using the more potent BCR::ABL1 tyrosine kinase inhibitors (eg, ponatinib, dasatinib) with the bispecific CD3-CD19 T-cell engager antibody blinatumomab in Philadelphia chromosome–positive ALL and combining blinatumomab and or inotuzumab (CD22 antibody drug conjugate) with standard chemotherapy in B-cell ALL
  • 3825-Acute lymphoblastic leukaemia ALL06 overview | eviQ
    Patients with leukaemia should be considered for inclusion into clinical trials Link to ALLG website and ANZCTR website This protocol is based on limited evidence; refer to the evidence section of this protocol for more information
  • How I treat newly diagnosed acute lymphoblastic leukemia
    Patients with B-ALL and detectable MRD should be treated with blinatumomab In the future, the use of blinatumomab and or inotuzumab ozogamycin in addition to first-line chemotherapy may become a new standard of care reducing the role of allo-HCT




Business Directories,Company Directories
Business Directories,Company Directories copyright ©2005-2012 
disclaimer